VALDAGNI, RICCARDO
VALDAGNI, RICCARDO
Dipartimento di Oncologia ed Emato-Oncologia
'Act on oncology' as a new comprehensive approach to assess prostate cancer centres : Method description and results of a pilot study
2014 W. Voigt, J. Hoellthaler, T. Magnani, V. Corrao, R. Valdagni
A Decade of Active Surveillance in the PRIAS Study : an Update and Evaluation of the Criteria Used to Recommend a Switch to Active Treatment
2016 L. Bokhorst, R. Valdagni, A. Rannikko, Y. Kakehi, T. Pickles, C. Bangma, M. Roobol, G. PRIAS study
A Deep Learning Approach Validates Genetic Risk Factors for Late Toxicity After Prostate Cancer Radiotherapy in a REQUITE Multi-National Cohort
2020 M. Massi, F. Gasperoni, F. Ieva, A. Paganoni, P. Zunino, A. Manzoni, N. Franco, L. Veldeman, P. Ost, V. Fonteyne, C. Talbot, T. Rattay, A. Webb, P. Symonds, K. Johnson, M. Lambrecht, K. Haustermans, G. De Meerleer, D. de Ruysscher, B. Vanneste, E. Van Limbergen, A. Choudhury, R. Elliott, E. Sperk, C. Herskind, M. Veldwijk, B. Avuzzi, T. Giandini, R. Valdagni, A. Cicchetti, D. Azria, M. Jacquet, B. Rosenstein, R. Stock, K. Collado, A. Vega, M. Aguado-Barrera, P. Calvo, A. Dunning, L. Fachal, S. Kerns, D. Payne, J. Chang-Claude, P. Seibold, C. West, T. Rancati
A monocentric, open-label randomized standard-of-care controlled study of XONRID®, a medical device for the prevention and treatment of radiation-induced dermatitis in breast and head and neck cancer patients
2020 R. Ingargiola, M. De Santis, N. Iacovelli, N. Facchinetti, A. Cavallo, E. Ivaldi, M. Dispinzieri, M. Franceschini, C. Giandini, D. Romanello, S. Di Biaso, M. Sabetti, L. Locati, S. Alfieri, P. Bossi, M. Guglielmo, F. Macchi, L. Lozza, R. Valdagni, C. Fallai, E. Pignoli, E. Orlandi
A multicenter LArge retrospectIve daTabase on the personalization of stereotactic ABlative radiotherapy use in lung metastases from colon-rectal cancer: The LaIT-SABR study
2022 L. Nicosia, D. Franceschini, F. Perrone-Congedi, F. Casamassima, M.A. Gerardi, M. Rigo, R. Mazzola, M. Perna, V. Scotti, A. Fodor, A. Iurato, F. Pasqualetti, G. Gadducci, S. Chiesa, R.M. Niespolo, A. Bruni, G. Alicino, L. Frassinelli, P. Borghetti, A. Di Marzo, A. Ravasio, B. De Bari, M. Sepulcri, D. Aiello, G. Mortellaro, C. Sangalli, M. Franceschini, G. Montesi, F.M. Aquilanti, G. Lunardi, R. Valdagni, I. Fazio, G. Scarzello, L. Corti, V. Vavassori, E. Maranzano, S.M. Magrini, S. Arcangeli, M.A. Gambacorta, V. Valentini, F. Paiar, S. Ramella, N.G. Di Muzio, L. Livi, B.A. Jereczek-Fossa, M.F. Osti, M. Scorsetti, F. Alongi
A Multivariable Approach Using Magnetic Resonance Imaging to Avoid a Protocol-based Prostate Biopsy in Men on Active Surveillance for Prostate Cancer-Data from the International Multicenter Prospective PRIAS Study
2022 H.B. Luiting, S. Remmers, E.R. Boevé, R. Valdagni, P.K. Chiu, A. Semjonow, V. Berge, K.H. Tully, A.S. Rannikko, F. Staerman, M.J. Roobol
Absorption rate density (ARD) computation in microwave hyperthermia by the finite-difference time-domain method
1990 R. Pontalti, L. Cristoforetti, R. Valdagni, R. Antolini
Active surveillance for low-risk prostate cancer
2013 C.H. Bangma, M. Bul, T.H. van der Kwast, T. Pickles, I.J. Korfage, C.M. Hoeks, E.W. Steyerberg, G. Jenster, M.W. Kattan, L. Bellardita, P.R. Carroll, L.J. Denis, C. Parker, M.J. Roobol, M. Emberton, L.H. Klotz, A. Rannikko, Y. Kakehi, J.A. Lane, F.H. Schröder, A. Semjonow, B.J. Trock, R. Valdagni
Active surveillance for low-risk prostate cancer : developments to date
2015 C.H. Bangma, R. Valdagni, P.R. Carroll, H. Van Poppel, L. Klotz, J. Hugosson
Active surveillance for low-risk prostate cancer Worldwide : The PRIAS study
2013 M. Bul, X. Zhu, R. Valdagni, T. Pickles, Y. Kakehi, A. Rannikko, A. Bjartell, D.K. Van Der Schoot, E.B. Cornel, G.N. Conti, E.R. Boevé, F. Staerman, J.J. Vis Maters, H. Vergunst, J.J. Jaspars, P. Strölin, E. Van Muilekom, F.H. Schröder, C.H. Bangma, M.J. Roobol
Acute patient-reported intestinal toxicity in whole pelvis IMRT for prostate cancer : Bowel dose-volume effect quantification in a multicentric cohort study
2021 A. Bresolin, A. Faiella, E. Garibaldi, F. Munoz, D. Cante, V. Vavassori, J.M. Waskiewicz, G. Girelli, B. Avuzzi, E. Villa, A. Magli, B. Noris Chiorda, M. Gatti, L. Ferella, A. Maggio, V. Landoni, S. Aimonetto, C. Sini, T. Rancati, G. Sanguineti, R. Valdagni, N. Di Muzio, C. Fiorino, C. Cozzarini
Adaptation and validation of an Italian version of the Prostate Cancer Specific Quality of Life Instrument (PROSQOLI)
2016 L. Bellardita, R. Damiano, F. Porpiglia, V. Scattoni, A. Amodeo, R. Bortolus, A. Lapini, A. Cocci, V. Cicalese, M. Caponera, P. Mastrangelo, F. Francesca, R. Valdagni, G. Taverna, D. di Trapani, R. Leonardi, D. Minocci, F. Gaboardi, E. Montanari, G. Conti
Almost one year of COVID-19 pandemic : how radiotherapy centers have counteracted its impact on cancer treatment in Lombardy, Italy. CODRAL/AIRO-L study
2021 B.A. Jereczek-Fossa, M.F. Palazzi, S. Tonoli, M. Zaffaroni, G. Marvaso, G.B. Ivaldi, M. Amadori, P. Antognoni, S. Arcangeli, A. Buffoli, G. Beltramo, M. Bignardi, S. Bracelli, A. De Stefani, S. Castiglioni, G. Catalano, N. Di Muzio, A. Cerrotta, L. Fariselli, A.R. Filippi, A. Gramaglia, C. Italia, P. Massaro, S.M. Magrini, S. Nava, E. Orlandi, N. Pasinetti, E.L. Sbicego, L. Scandolaro, M. Scorsetti, C. Barbonetti, R. Tortini, R. Valdagni, V. Vavassori, M. Pepa, L.F. Cazzaniga, C.P. Soatti
An accurate method to quantify breathing-induced prostate motion for patients implanted with electromagnetic transponders
2017 T. Giandini, C. Panaino, B. Avuzzi, S. Morlino, S. Villa, N. Bedini, G. Carabelli, S. Frasca, A. Romanyukha, A. Rosenfeld, E. Pignoli, R. Valdagni, M. Carrara
Back to (new) normality-A CODRAL/AIRO-L survey on cancer radiotherapy in Lombardy during Italian COVID-19 phase 2
2020 B. Jereczek-Fossa, M. Pepa, G. Marvaso, J. Isaksson, C. Soatti, L. Cazzaniga, G. Ivaldi, M. Amadori, P. Antognoni, S. Arcangeli, A. Buffoli, G. Beltramo, M. Bignardi, S. Bracelli, L. Bruschieri, S. Castiglioni, G. Catalano, N. Di Muzio, C. Fallai, L. Fariselli, A. Filippi, A. Gramaglia, C. Italia, F. Lombardi, S. Magrini, S. Nava, E. Orlandi, N. Pasinetti, E. Sbicego, L. Scandolaro, M. Scorsetti, F. Stiglich, R. Tortini, R. Valdagni, V. Vavassori, S. Tonoli, M. Palazzi
Baseline status and dose to the penile bulb predict impotence 1 year after radiotherapy for prostate cancer
2016 C. Cozzarini, T. Rancati, F. Badenchini, F. Palorini, B. Avuzzi, C. Degli Esposti, G. Girelli, I. Improta, V. Vavassori, R. Valdagni, C. Fiorino
Beam modifying devices in the treatment of early breast cancer: 3-D stepped compensating technique
1992 R. Valdagni, M. Ciocca, L. Busana, A. Modugno, C. Italia
Bladder spatial-dose descriptors correlate with acute urinary toxicity after radiation therapy for prostate cancer
2016 I. Improta, F. Palorini, C. Cozzarini, T. Rancati, B. Avuzzi, P. Franco, C. Degli Esposti, E. Del Mastro, G. Girelli, C. Iotti, V. Vavassori, R. Valdagni, C. Fiorino
Breast cancer patient perspective on opportunities and challenges of a genetic test aimed to predict radio-induced side effects before treatment : Analysis of the Italian branch of the REQUITE project
2021 L. Bellardita, R.R. Colciago, S. Frasca, M.C. De Santis, S. Gay, F. Palorini, E. La Rocca, R. Valdagni, T. Rancati, L. Lozza
Can active surveillance really reduce the harms of overdiagnosing prostate cancer? A reflection of real life clinical practice in the PRIAS study
2018 F.-.H. Drost, A. Rannikko, R. Valdagni, T. Pickles, Y. Kakehi, S. Remmers, H.G. van der Poel, C.H. Bangma, M.J. Roobol